Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today that its Chief Executive Officer, Dr. George Adams, will present Amorfix's EP-vCJD(TM) blood screening test for variant Creutzfeldt-Jakob Disease ("vCJD") at the Sixth World Federation of Hemophilia ("WFH") Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders in Montreal, Quebec at 11:00 am ET on Friday, September 25, 2009.
WFH Global Forums bring together patient groups, regulators, representatives from industry and not-for-profit fractionators, as well as doctors who treat people with bleeding disorders to address the safety and supply of blood and plasma fractions for bleeding disorders.
Dr. Adams commented, "Early this year, the UK Health Protection Agency confirmed the first case of vCJD in one of the thousands of hemophiliac patients who received potentially contaminated plasma fractions. While the patient ultimately died of causes other than vCJD, this news has served to amplify the calls from hemophilia patients in the UK and around the world for their respective governments to protect the blood supply through routine testing of blood donations. Universal testing would provide peace of mind for hemophiliacs and their families and identify anyone already incubating vCJD so counseling could be provided to potential victims."
"My message at the WFH Global Forum will be one of hope in starting to answer those calls," continued Dr. Adams. "As previously reported, a total of 30,000 blood donations have been collected and tested with our EP-vCJD(TM) screening assay at two blood transfusion centers in France. In both centers using two lots of test kits, the EP-vCJD(TM) screening test performed better than the 99.85% specificity required by the UK Blood Transfusion Service and therefore meets the required performance standard for routine testing."
AMORFIX LIFE SCIENCES LTD.